Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
229 Leser
Artikel bewerten:
(0)

Edison Awards Recognize Ortho Clinical Diagnostics for Outstanding Product Innovation

RARITAN, New Jersey, April 21, 2017 /PRNewswire/ -- Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that it has been awarded an Edison Award' for Global Product Innovation,for its ORTHO VISION® Platform. ORTHO VISION is a portfolio of fully automated analyzers that test blood for compatibility with patients receiving blood transfusions.

Photo - https://mma.prnewswire.com/media/492772/Ortho_Clinical_Diagnostics_ORTHO_VISION_Max.jpg

The ORTHO VISION® Platform is comprised of the ORTHO VISION and ORTHO VISION Max analyzers. Tailored to the needs of blood banks or hospitals, the ORTHO VISION platform helps improve workflow and supports the standardization of systems and processes, enabling labs to increase productivity while remaining operationally efficient. The distinguished Edison Award honors the products, services and solutions that represent the best in innovation from around the world.

"With comprehensive testing capabilities, the ORTHO VISIONplatform enables labs to automate their immunohematology testing menu. This helps labs deliver accurate results, even during staffing shortages and in the face of cost constraints," said Heidi Casaletto, vice president Transfusion Medicine at Ortho. "This prestigious recognition from The Edison Awards acknowledges our commitment to innovating and reimagining what's possible for our customers."

The innovative ORTHO VISION platform introduces:

  • Continuous access during testing - The ORTHO VISION platform helps labs manage the flow of incoming orders and reduces the need to batch samples. It allows for organizing and prioritization of STAT requests without disrupting existing testing queues, a critical advantage in helping hospitals respond to crises
  • e-Connectivity' Technology - Ortho specialists remotely monitor the ORTHO VISION Analyzer's performance, so they can intervene to predict and prevent issues before they occur.
  • Proprietary Intellicheck® Technology - Verifies, documents, and resolves diagnostic checks throughout sample processing.
  • Virtual collaboration - Lab staff can log on from the hospital and/or blood bank network for real-time interaction to review results.
  • Standardization -- ORTHO VISION and ORTHO VISION Max are the only immunohematology analyzers available today that are built on the same instrumentation platform. This creates lab standardization across instrumentation, technology, procedures, training and quality, which leads to greater consistency across workflows and staff proficiency.

In addition to this Edison Award, earlier this year, Ortho received two Global Business Excellence Awards, which honored the ORTHO VISION platform for its innovation and excellence. Also this year, Ortho was honored with an internationally recognized Gold Stevie Award for Global Customer Service for Ortho Care', a comprehensive collection of high-quality lab services and resources provided to Ortho customers at hospitals, hospital networks, blood banks and independent labs to enhance their overall performance.

About Ortho Clinical Diagnostics
Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the global clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks, and labs in more than 120 countries, Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions. For the immunohematology community, Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's purpose is to improve and save lives with diagnostics, and it does that by reimagining what's possible. This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward. For more information, visit www.orthoclinicaldiagnostics.com.

Ortho Care' is a trademark of Ortho Clinical Diagnostics.
ORTHO VISION® is a trademark of Ortho Clinical Diagnostics

© Ortho Clinical Diagnostics 2017
PR-02841

logo

Logo - https://mma.prnewswire.com/media/376902/ocd_only_black_Logo.jpg

© 2017 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.